Nuvectis Pharma, Inc. (NVCT) Documents: SEC Filings, Investor Presentations & Press Releases

Nuvectis Pharma, Inc. (NVCT) documents, SEC filings and the IR site together: 74 documents, newest first; latest 2026-08-21. Read in-app with summaries. First-party data.

Documents — U.S. SEC EDGAR and the company's IR site

Date	Type	Document
2026-08-21	8-K	Form 8-K, Item 8.01
2026-08-04	8-K	Form 8-K, Item 2.02 results
2026-08-04	10-Q	Form 10-Q for the quarter ended Jun 30
2026-07-05	Deck	https://storage.googleapis.com/vendorgroup-assets/site/06c2e337-3f91-4e38-96b4-7264f3c8b7c9/2026/07/06/6a4b2a9181712e94d
2026-06-30	8-K	Form 8-K, Item 1.01
2026-06-29	8-K	Form 8-K, Item 8.01
2026-06-23	8-K	Form 8-K, Item 1.01
2026-06-12	8-K	Form 8-K, Item 5.07
2026-05-10	Deck	Corporate Presentation (May 2026)
2026-05-05	8-K	Form 8-K, Item 2.02 results
2026-05-05	10-Q	Form 10-Q for the quarter ended Mar 31
2026-04-27	Proxy	Definitive proxy statement
2026-02-11	8-K	Form 8-K, Item 2.02 results
2026-02-11	10-K	Annual report on Form 10-K, FY25
2025-12-20	Deck	NXP900 Phase 1b KOL Event (December 2025)
2025-11-04	8-K	Form 8-K, Item 2.02 results
2025-11-04	10-Q	Form 10-Q for the quarter ended Sep 30
2025-09-25	8-K	Form 8-K, Item 5.02
2025-08-05	8-K	Form 8-K, Item 2.02 results
2025-08-05	10-Q	Form 10-Q for the quarter ended Jun 30
2025-06-13	8-K	Form 8-K, Item 5.07
2025-05-09	8-K	Form 8-K, Item 8.01
2025-05-06	8-K	Form 8-K, Item 2.02 results
2025-05-06	10-Q	Form 10-Q for the quarter ended Mar 31
2025-04-28	Proxy	Definitive proxy statement
2025-02-25	8-K	Form 8-K, Item 2.02 results
2025-02-25	10-K	Annual report on Form 10-K, FY24
2025-02-06	8-K	Form 8-K, Item 1.01
2024-11-05	8-K	Form 8-K, Item 2.02 results
2024-11-05	10-Q	Form 10-Q for the quarter ended Sep 30
2024-08-29	8-K	Form 8-K, Item 8.01
2024-08-06	8-K	Form 8-K, Item 2.02 results
2024-08-06	10-Q	Form 10-Q for the quarter ended Jun 30
2024-06-13	8-K	Form 8-K, Item 5.07
2024-05-07	8-K	Form 8-K, Item 2.02 results
2024-05-07	10-Q	Form 10-Q for the quarter ended Mar 31
2024-04-29	Proxy	Definitive proxy statement
2024-03-05	8-K	Form 8-K, Item 2.02 results
2024-03-05	10-K	Annual report on Form 10-K, FY23
2023-11-08	8-K	Form 8-K, Item 2.02 results

NVCT overview · NVCT earnings · NVCT financials · NVCT KPIs · NVCT ownership · NVCT peers

Data sourced from U.S. SEC EDGAR and the company's investor-relations site. Not personalized investment advice.